Survival Outcomes of Advanced Thyroid Cancer Enriched in Brain Metastases Following Treatment With Small Molecule Inhibitors
Authors' conclusion
This single-institutional analysis reports survival outcomes of 116 patients with advanced thyroid cancer on targeted therapies, including 18 patients with brain metastases. Mutation-directed therapy for BRAFV600E mutations, RET mutations, RET fusions, and NTRK fusions had superior survival.
Study context
- Population
- Patients with thyroid carcinomas who received ≥1 SMI (lenvatinib, sorafenib, dabrafenib-trametinib, selpercatinib, cabozantinib), 2008–2022; 49.1% female, median age 61.1 years; PTC 49.6%, ATC 19.8%, MTC 19.8%, FTC 11.2%
- Participants
- 116 patients
- Exposure
- Brain metastasis vs visceral metastasis in thyroid cancer on SMI
- Brain metastasisn = 18
- Visceral metastasisn = 98reference
- Outcome
- OS, defined from detection of first metastasis
Methodological detailssingle-institution, tertiary academic centre
- Single-institution
- Tertiary academic centre
Main finding
As reported in the abstract
OS
P = 0.44
Observational data: associations, not effects.
Further findings
OS excluding ATC · not different
P = 0.21
OS in PTC · trend toward worse OS with brain metastasis
P = 0.13
Factors associated with improved overall survival (OS)
- Total thyroidectomy, OR
- 40.0; P <.001
- Number of unique therapies, OR
- 10.9; P =.047
- Mutation-directed therapy, OR
- 24.7; P =.003
- Nonanaplastic histology associated with improved OS
Original publication
Survival Outcomes of Advanced Thyroid Cancer Enriched in Brain Metastases Following Treatment With Small Molecule Inhibitors. Endocr Pract. Published 18 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →